UNSPSC 51333005: Tienocarbine

This classification denotes an antipsychotic agent with the molecular formula C15H16N2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier B255B0J51N, chemically known as 7,8,9,10-tetrahydro-1,9-dimethyl-6h-pyrido(4,3-b)thieno(3,2-e)indole but generally known as tienocarbine, which bears US NIH Compound Identifier 71140. European Medicines Agency schedules Tienocarbine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11033MIG.

UNSPSC 51333005 Tienocarbine, a Commodity code, does not align with the state and local procurement activity recently tagged under it. The three recent opportunities solicited naloxone and safe drug deactivation systems (Seminole County, Florida), therapeutic pharmacy initiatives for direct-to-manufacturer prescriptions (Texas Health and Human Services Commission), and generic multi-source pharmaceuticals and over-the-counter products distributed through cooperative purchasing (Minnesota Multistate Cooperative Purchasing Alliance). None of these solicitations reference tienocarbine, an antibiotic compound used in human medicine. The mismatch suggests either miscategorization in the tagging system or a data alignment issue between the code assignment and the actual scope of work being procured.

The recent opportunities show state health and human services agencies and county health departments soliciting pharmaceutical products and systems through competitive bidding and cooperative purchasing mechanisms. Issuing bodies include county health departments (Seminole County), state HHS commissions (Texas), and multistate cooperative purchasing alliances serving state and local facilities across multiple jurisdictions (Minnesota MMCAP covering Minnesota and Oregon participants). Geographic activity concentrates in Florida, Texas, and the upper Midwest, with MMCAP extending purchasing benefits to state and local users nationwide. Representative solicitations include Seminole County's IFB60459723LAS for naloxone and drug deactivation systems (IFB, due July 26, 2023), Texas HHS's RFI HHS0017013 on direct-to-manufacturer prescriptions (RFI, April 3, 2026 response deadline), and MMCAP's S1070000015802 for generic pharmaceuticals and OTC products through cooperative purchasing (RFP, due March 26, 2026). Without recent opportunities directly addressing tienocarbine, the code shows little relevant current activity.